Optimi Health (CSE: OPTI) recently announced the successful completion of the first export of its GMP-validated MDMA capsules to Australia. This export is intended for the treatment of post-traumatic stress disorder (PTSD) under Australia’s Authorised Prescriber Scheme. The company stated that the first group of patients will commence MDMA-assisted therapy capsules in the upcoming weeks, utilizing its GMP-validated 40mg and 60mg MDMA capsules.
This development signifies a significant milestone for Optimi Health in its efforts to gather real-world evidence and patient-reported outcomes for MDMA-assisted therapy in PTSD patients in Australia. Additionally, the company has obtained an export permit from Health Canada to send its first shipment of validated GMP natural psilocybin extract to the Matai Medical Research Institute in New Zealand, where it will be utilized in a pilot study assessing the feasibility, acceptability, and safety of administering psychedelic-assisted therapies to healthy volunteers.
Headquartered in Vancouver, Optimi Health is a licensed psychedelics pharmaceutical manufacturer by Health Canada, specializing in controlled substances such as botanical psilocybin and MDMA. The shares of Optimi Health Corp. (CSE: OPTI) have increased by 1.67 per cent to C$0.30 as of 10:05 am ET.
For more information and investor discussions regarding this stock, individuals can visit the Optimi Health Corp. Bullboard on Stockhouse’s investor discussion forum. Please note that the content provided in this article is for informational purposes only and should not be considered as investment advice. For a full disclaimer, please refer to the provided link.
